PATENT CLAIM ANALYSIS

Application Number: 16195661
Application Type: Utility
Filing Date: 2018-11
Publication Date: 2019-10
Patent Classification: ["514", "001900"]

Abstract:
Leptin, leptin analogs, and leptin derivatives are used to treat patients with lipoatrophy. Leptin is effective against conditions of lipoatrophy for both genetic and acquired forms of the disease. A therapeutically effective amount of leptin can be administered in a variety of ways, including subcutaneously and using gene therapy methods. Methods of the present invention contemplate administration of leptin, leptin analogs, and leptin derivatives to patients having a leptin level of approximately 4 ng/ml or less before treatment.

Claim (Index 28):
A method of determining a predisposition of a lipoatrophic patient to respond to treatment with leptin, leptin analog, or leptin derivative, the method comprising:\n (a) determining a leptin level in the patient prior to said treatment; and (b) ascertaining whether the leptin level of (i) a male patient is less than or equal to approximately 2 ng/ml, or (ii) a female patient is less than or equal to approximately 4 ng/ml.

Metadata:
- Claim Count in Document: 8.0
- Percentile: 98.0
- Lexical Diversity: 1.55357
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['10623189', '13103294', '12995842', '11821221', '10286947']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7719383847125317
- 35 USC 102 Novelty (BERT): 0.5996019788276037
- Combined Prediction Score: 0.754704744124039
- Mean Citation Score: 356.92271800000015
- Max Citation Score: 521.53766
- Similarity Product: 484.50750183077565

Labels:
- Claim Label 101: 0
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 0
- Label 101 Adjusted: 0

Dataset: test